Weekly Spotlight - 19.12.24

Community

Share Your Story, Inspire Hope

Your journey can be a beacon of hope and a source of strength for others in our community. Together, we can build a stronger, more supportive community. Your story matters, and it deserves to be heard. Fill in this form to be featured.

Latest News

First New Drug for Rare Hormonal Disorder in 70 Years Approved

Neurocrine's Cressity is the first new drug approved for congenital adrenal hyperplasia (CAH) in 70 years, offering a significant advancement in treatment. It targets the underlying hormonal imbalance, providing an alternative to traditional steroid therapies and potentially improving quality of life for CAH patients.

FDA Approves Crinecerfont for Rare Hormonal Disorder After Successful Phase 3 Trial

Dr. Richard J. Auchus discusses a pivotal Phase 3 trial that led to the FDA approval of crinecerfont, a treatment for congenital adrenal hyperplasia. The trial showed crinecerfont's effectiveness in reducing androgen levels, improving symptoms and quality of life for patients with this condition.

Breakthrough Therapy for Rare Hormonal Disorder Shows Promise in 2024 Studies

Experts discuss a new breakthrough therapy for congenital adrenal hyperplasia, highlighting the potential of a novel treatment that could significantly improve patient outcomes. Dr. Richard Auchus, MD, PhD, shares insights on this innovative approach and its implications for managing the condition.